vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($395.6M vs $207.8M, roughly 1.9× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 24.0%, a 33.4% gap on every dollar of revenue.
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
DLB vs IDYA — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $395.6M | $207.8M |
| Net Profit | $94.9M | $119.2M |
| Gross Margin | 88.7% | — |
| Operating Margin | 28.5% | 52.2% |
| Net Margin | 24.0% | 57.4% |
| Revenue YoY | 7.1% | — |
| Net Profit YoY | 3.4% | 330.1% |
| EPS (diluted) | $0.99 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | — | ||
| Q3 25 | $307.0M | $207.8M | ||
| Q2 25 | $315.5M | — | ||
| Q1 25 | $369.6M | — | ||
| Q4 24 | $357.0M | — | ||
| Q3 24 | $304.8M | $0 |
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | — | ||
| Q3 25 | $49.3M | $119.2M | ||
| Q2 25 | $46.1M | — | ||
| Q1 25 | $91.8M | — | ||
| Q4 24 | $67.8M | — | ||
| Q3 24 | $58.6M | $-51.8M |
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | — | ||
| Q3 25 | 87.1% | — | ||
| Q2 25 | 86.1% | — | ||
| Q1 25 | 90.3% | — | ||
| Q4 24 | 88.6% | — | ||
| Q3 24 | 88.8% | — |
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | — | ||
| Q3 25 | 9.7% | 52.2% | ||
| Q2 25 | 15.1% | — | ||
| Q1 25 | 29.2% | — | ||
| Q4 24 | 22.4% | — | ||
| Q3 24 | 15.2% | — |
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | — | ||
| Q3 25 | 16.1% | 57.4% | ||
| Q2 25 | 14.6% | — | ||
| Q1 25 | 24.8% | — | ||
| Q4 24 | 19.0% | — | ||
| Q3 24 | 19.2% | — |
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | — | ||
| Q3 25 | $0.50 | $1.33 | ||
| Q2 25 | $0.48 | — | ||
| Q1 25 | $0.94 | — | ||
| Q4 24 | $0.70 | — | ||
| Q3 24 | $0.59 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $594.7M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $1.1B |
| Total Assets | $3.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | — | ||
| Q3 25 | $702.6M | $786.9M | ||
| Q2 25 | $699.3M | — | ||
| Q1 25 | $626.6M | — | ||
| Q4 24 | $520.8M | — | ||
| Q3 24 | $482.0M | $920.0M |
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | $1.1B | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | $1.2B |
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.2B | $1.2B | ||
| Q2 25 | $3.2B | — | ||
| Q1 25 | $3.2B | — | ||
| Q4 24 | $3.2B | — | ||
| Q3 24 | $3.1B | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.3M | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 1.55× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | — | ||
| Q3 25 | $472.2M | $142.2M | ||
| Q2 25 | $67.7M | — | ||
| Q1 25 | $174.9M | — | ||
| Q4 24 | $106.8M | — | ||
| Q3 24 | $327.3M | $-49.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | — | ||
| Q3 25 | $435.9M | $142.2M | ||
| Q2 25 | $61.3M | — | ||
| Q1 25 | $168.0M | — | ||
| Q4 24 | $100.0M | — | ||
| Q3 24 | $297.2M | $-49.7M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | — | ||
| Q3 25 | 142.0% | 68.4% | ||
| Q2 25 | 19.4% | — | ||
| Q1 25 | 45.5% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 97.5% | — |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | — | ||
| Q3 25 | 11.8% | 0.0% | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 9.8% | — |
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | — | ||
| Q3 25 | 9.57× | 1.19× | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.91× | — | ||
| Q4 24 | 1.57× | — | ||
| Q3 24 | 5.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
IDYA
Segment breakdown not available.
